Semaglutide, Muscle Loss and Bone Density

Muscle carries you up stairs and out of chairs, and it protects you in a fall. From midlife onward it declines on its own, slowly at first and faster later. When that loss reaches the point where strength and function suffer, it has a name: sarcopenia.

The 2025 advisory names the people most at risk of losing muscle on a GLP-1: older adults, women around and after menopause, men with lower testosterone, people who are sedentary, and anyone not doing resistance training. That list describes a large part of the population we see.

The other problem is that muscle lost at 55 comes back more slowly than muscle lost at 30. No study has yet measured whether weight regained after stopping a GLP-1 returns as fat or as muscle; the 2026 regain meta-analysis lists it as an open question. The advisory's concern is that repeated loss and regain, without training and adequate nutrition, can leave someone with sarcopenic obesity: body weight back where it started, with less muscle underneath. If you have noticed your body changing shape without the number changing much, muscle loss versus fat gain explains how to tell the two apart.

Bone responds to load. Carry less weight and the skeleton gets a smaller signal to maintain itself, so substantial weight loss, by any method, is associated with some bone loss. The advisory notes that weight loss that is large and rapid is linked to significant bone loss, that slower and more moderate loss appears to preserve bone better, and that older adults and women tend to lose more.

The most useful trial here did not use semaglutide. A Danish randomized trial published in JAMA Network Open in 2024 followed adults with obesity for a year after an initial diet. Those on liraglutide, an older GLP-1 medication, without exercise lost bone density at the hip and spine compared with placebo. Those who combined liraglutide with a structured exercise program kept their bone density at the hip, spine and forearm despite losing more weight. It is one trial, of a different drug, in people under 65. But it points the same way as everything else here: the medication does not decide the outcome on its own.

Weight alone cannot show any of this, so we do not rely on it.

• Body composition at baseline and on follow-up. We measure before you start and again on the cadence your clinician sets, so fat lost and lean mass lost are separate lines on your chart.
• How you function, not only how you measure. Your clinician asks about the things that show strength first: climbing stairs, carrying shopping, getting up from a low chair, any new unsteadiness or falls.
• The labs this treatment depends on. Your prescribing clinician reviews the labs this treatment depends on, which may include markers relevant to bone such as vitamin D, depending on your history. The full approach is on labs and monitoring on semaglutide.

If lean mass is falling faster than your clinician is comfortable with, the plan changes. That can mean more emphasis on training and protein, a slower pace, or a different approach altogether, decided with your clinician from your own numbers.

Of everything you can do, this has the strongest evidence. The advisory is direct: structured strength training, or strength training mixed with aerobic exercise, is well established for preserving lean mass during weight loss, and aerobic exercise alone does less.

The US Physical Activity Guidelines ask every adult for muscle-strengthening activity on at least 2 days each week, alongside aerobic activity, and note that in older adults activity also lowers the risk of falls.

In practice that means working every major muscle group against resistance that feels genuinely hard by the last few repetitions, and making it slightly harder over time. Free weights, machines, bands and bodyweight all work. If you are new to it, or have a joint problem, a physical therapist or qualified trainer can set you up safely. Consistency over months matters more than intensity in the first week.

Reduced appetite is how the medication works, and it is also how people end up eating too little protein without noticing. Low protein intake on a GLP-1 contributes to muscle loss, particularly in older adults.

The practical fixes are simple:

• Eat the protein on your plate first, before the starch, so it is not what gets left behind when fullness arrives. The advisory recommends exactly this.
• Spread it across the day rather than loading it into dinner.
• Choose sources that also do other jobs: fish and seafood, eggs, dairy such as yogurt, lean poultry, and beans, lentils and peas.

We do not publish a single protein target on this page, because the right figure depends on your size, your body composition, your kidney function and your training. Your clinician or a dietitian can set yours. The what to eat on semaglutide page covers meals in more detail, and our guide to protein sources for muscle after 45 compares the options.

A bone density scan, usually a DEXA scan of the hip and spine, is quick and uses very low levels of radiation. We do not perform it ourselves; we refer you for one when it is warranted. We would rather have one on file before you start if any of these apply:

• You are a woman aged 65 or older. The US Preventive Services Task Force recommends osteoporosis screening for all women in this group.
• You are postmenopausal and younger than 65 with a risk factor. The Task Force recommends screening for these women too.
• You have had a fracture after age 50, have noticeably lost height, have a low body weight, or have a parent with osteoporosis.
• You have other bone risk factors such as long-term smoking or heavy drinking, low physical activity, or conditions such as diabetes or rheumatoid arthritis.

For men, the Task Force found the evidence insufficient to recommend routine screening either way. That makes it an individual decision rather than a no, and an older man with risk factors who is planning substantial weight loss is a reasonable candidate.

A scan before treatment gives a reference point. If it shows low bone density, that changes the conversation: the pace of weight loss, the training plan, calcium and vitamin D intake, and whether bone-specific treatment from your primary care physician or a specialist makes sense first. For women in menopause, estradiol and bone density covers the hormonal side.

If you are over 60, have already lost strength or function, have had a fall in the last year, or have unintentionally lost weight recently, the balance shifts. In that person, losing more muscle can cost more than the weight loss gains, and sometimes the right order is to build strength first and treat later. Semaglutide after 60 covers how the assessment changes with age.